Quadrature Capital Ltd Buys 89,217 Shares of Insmed, Inc. $INSM

Quadrature Capital Ltd raised its stake in Insmed, Inc. (NASDAQ:INSM) by 1,191.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 96,703 shares of the biopharmaceutical company’s stock after purchasing an additional 89,217 shares during the quarter. Quadrature Capital Ltd’s holdings in Insmed were worth $9,732,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of INSM. Chung Wu Investment Group LLC purchased a new position in Insmed during the 2nd quarter worth $173,000. Caxton Associates LLP bought a new position in shares of Insmed during the first quarter valued at about $441,000. Assenagon Asset Management S.A. boosted its holdings in Insmed by 84.5% during the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new position in Insmed during the second quarter worth about $5,578,000. Finally, Intech Investment Management LLC grew its position in Insmed by 43.2% in the 1st quarter. Intech Investment Management LLC now owns 101,979 shares of the biopharmaceutical company’s stock worth $7,780,000 after purchasing an additional 30,752 shares in the last quarter.

Insmed Stock Up 0.9%

Shares of NASDAQ INSM opened at $206.43 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a market capitalization of $44.02 billion, a PE ratio of -36.15 and a beta of 1.05. Insmed, Inc. has a one year low of $60.40 and a one year high of $209.77. The business’s fifty day moving average price is $173.90 and its 200-day moving average price is $129.63.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company’s revenue was up 52.4% compared to the same quarter last year. During the same period last year, the business posted ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, Director Leo Lee sold 75,000 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the sale, the director owned 54,677 shares of the company’s stock, valued at $10,711,224.30. The trade was a 57.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the transaction, the insider directly owned 54,902 shares of the company’s stock, valued at $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 257,922 shares of company stock worth $44,556,283 in the last ninety days. Insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on INSM. Mizuho set a $196.00 target price on Insmed in a research note on Wednesday, October 29th. Morgan Stanley lifted their price target on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. UBS Group upped their price objective on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st. The Goldman Sachs Group lifted their target price on Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. increased their price target on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $175.53.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.